Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof

Patent metadata

Field	Value
Publication number	US-9566343-B2
Application number	US-201414336549-A
Country	US
Kind code	B2
Filing date	Jul 21, 2014
Priority date	Oct 26, 2011
Publication date	Feb 14, 2017
Grant date	Feb 14, 2017

Abstract

The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydromorphone (4,5-α-epoxy-3-hydroxy-17-methyl morphinan-6-one) to form novel prodrugs/compositions of hydromorphone. The hydromorphone prodrugs of the present technology have decreased side effects and decreased potential for abuse compared to unconjugated hydromorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.

First claim

The invention claimed is:

1. A composition comprising at least one conjugate, wherein the at least one conjugate is 3-aspirin-hydromorphone.

2. The composition of claim 1 , wherein the at least one conjugate is used to treat narcotic or opioid abuse; to prevent narcotic or opioid withdrawal; to treat moderate to severe pain; to reduce or prevent oral, intranasal or intravenous drug abuse; or to provide oral, intranasal or parenteral drug abuse resistance.

3. The composition of claim 2 , wherein oral administration of the at least one conjugate results in an improved rate of release over time when compared to unconjugated hydromorphone over the same time period.

4. The composition of claim 2 , wherein oral administration of the at least one conjugate results in less variability in the oral PK profile when compared to unconjugated hydromorphone.

5. The composition of claim 2 , wherein oral administration of the at least one conjugate results in reduced side effects when compared with unconjugated hydromorphone.

6. The composition of claim 5 , wherein the reduced side effect is reduced opioid induced constipation.

7. The composition of claim 1 , wherein the at least one conjugate is provided in a dosage form selected from the group consisting of a tablet, a capsule, a caplet, a suppository, a troche, a lozenge, an oral powder, a solution, an oral film, a thin strip, a slurry, and a suspension.

8. The composition of claim 2 , wherein oral administration of the at least one conjugate provides a therapeutically bioequivalent AUC and/or a bioequivalent when compared to an equivalent molar amount of unconjugated hydromorphone.

9. The composition of claim 2 , wherein intranasal or intravenous administration of the at least one conjugate provides a lower AUC and/or C max when compared to an equivalent molar amount of unconjugated hydromorphone.

10. The composition of claim 2 , wherein oral administration of the at least one conjugate provides a decreased overdose potential when compared to an equivalent molar amount of unconjugated hydromorphone.

11. The composition of claim 1 , wherein the at least one conjugate provides an increased tamper resistance when compared to unconjugated hydromorphone.

12. A composition comprising 3-aspirin-hydromorphone, having the following structure:

Assignees

• Kempharm Inc

Inventors

• Mickle Travis
• Guenther Sven
• Chi Guochen
• Kanski Jaroslaw
• Martin Andrea K
• Bera Bindu

Classifications

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title

• A61P25/36

  Opioid-abuse · CPC title

• A61P11/14

  Antitussive agents · CPC title

• A61K31/485 Primary

  Morphinan derivatives, e.g. morphine, codeine · CPC title